Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could cutting dialysis sessions in half improve life for seniors?

NCT ID NCT07738731

Disease control Sponsor: Queen's University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 31, 2026 · Last updated Jul 31, 2026

Summary

This study tests whether elderly patients starting dialysis for kidney failure can receive treatments twice a week instead of the usual three times, without increasing hospitalizations or death. The goal is to see if fewer sessions allow patients to spend more days at home and improve their quality of life. Researchers will compare outcomes like days alive and out of hospital, overall well-being, and healthcare costs between the two treatment schedules.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Twice weekly hemodialysis compared to thrice weekly hemodialysis
What this could lead to
If fewer dialysis sessions work as well, elderly patients could spend more time at home and enjoy a better quality of life, while easing the burden on healthcare and the environment.
What could go wrong
This is a large but still early-stage study; results may not apply to all patients, and there is a risk that less frequent dialysis could lead to worse health outcomes for some.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 210 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Oct 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

70 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. patients aged 70 or above 2. have developed end stage kidney disease and require hemodialysis treatment Exclusion Criteria: 1. Hospitalized patients without an alternate level of care designation 2. Those with missed hemodialysis sessions due to non-adherence during the first 7 weeks of hemodialysis treatment 3. Patients already prescribed twice weekly hemodialysis 4. Patients who are medically unsuitable as per primary care team and site investigator 5. anticipated significant barriers to ascertainment of patient-reported experience measures

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage kidney disease (ESKD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End-stage kidney disease (ESKD) Hemodialysis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHUM

    Montreal, Quebec, Canada

  • Centre de Recherche du CHU de Quebec: Laval University

    Québec, Quebec, Canada

  • Dalhousie University

    Halifax, Nova Scotia, Canada

  • Hopital Maisoneuve-Rosemont

    Montreal, Quebec, Canada

  • Hopital du Sacre-Coeur-de-Montreal

    Montreal, Quebec, Canada

  • Hopital du Sacre-Coeur-de-Montreal

    Montreal, Quebec, Canada

  • Hôpital du Haut-Richelieu

    Montreal, Quebec, Canada

  • McGill University

    Montreal, Quebec, Canada

  • Memorial University

    St. John's, Newfoundland and Labrador, Canada

  • Multiple Sites

    Vancouver, British Columbia, Canada

  • Queen's University

    Kingston, Ontario, K7L 4B7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.